WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, today announced that it is making available its white
paper, From Biologics to Biosimilars - How Will the Market Evolve?
Addressing timing, hurdles that must be overcome and ultimately who has the
most to lose, this paper guides readers through the biologics/biosimilars
conundrum with the aid of data and analysis from Pharmaview.
Topics covered in the white paper include:
-- Patent expiries and anticipated biosimilar entry dates for key biologic
-- Companies at risk from biosimilars
-- Who the key competitors will be in the biosimilars market
If you would like to download a copy of the white paper, please visit: http://www.decisionresources.com/form/downloads/Pharmaview-WhitePaper.pdf
Pharmaview provides continually updated analysis on over 1,500 marketed and pipeline products from over 120 companies, covering 136 product classes and 14 therapy areas - complete with seven-year product-level forecasts for over 1,000 products.
About Decision Resources
Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Heather Hilty Elizabeth Marshall
Decision Resources Decision Resources, Inc.
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved